CClinicalTrials.gg
RecruitingNCT07469033Updated Mar 13, 2026

Prevalence of Misophonia in Turkish High School Students

An observational study in Misophonia, sponsored by Ondokuz Mayıs University. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 15 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Ondokuz Mayıs University · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 8 months later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
600
Ages
15 Years to 18 Years
Sex
All
01

Study summary

This cross-sectional study aims to determine the prevalence of misophonia among high school students in Kayseri and Samsun, Turkey. Data will be collected using a sociodemographic data form and the Amsterdam Misophonia Scale-Revised (AMISOS-R). The study will evaluate the frequency and severity of misophonia symptoms and examine their association with demographic variables.

Read the detailed description

Misophonia is a condition characterized by decreased tolerance and heightened sensitivity to specific sounds. It is more closely related to the character of the sound than to its intensity and is often reported to begin during childhood or early adolescence. Misophonia may negatively affect students' social interactions and academic performance, particularly in school environments where exposure to auditory stimuli is unavoidable.

This cross-sectional descriptive prevalence study aims to determine the prevalence and severity of misophonia among high school students in Kayseri and Samsun, Turkey. The study population will include students in grades 9 through 12 attending selected high schools. Students with hearing loss, chronic illness, severe psychological disorders, intellectual disabilities, or those outside the defined age range will be excluded.

Data will be collected using a sociodemographic data form and the 10-item Amsterdam Misophonia Scale-Revised (AMISOS-R), a validated self-report instrument assessing the presence and severity of misophonia symptoms. Statistical analyses will be conducted to evaluate the distribution of misophonia symptoms and their associations with demographic variables. The study will be conducted in accordance with ethical principles.

02

Conditions studied

  • Misophonia

Keywords

  • AMISOS-R
  • High school students
  • Prevalence
03

In context

Lead sponsor

Ondokuz Mayıs University is the lead sponsor of 262 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

High school students in grades 9 through 12 from selected schools in Kayseri and Samsun, Turkey.

Inclusion criteria

  • Students enrolled in grades 9 through 12
  • Students without diagnosed hearing loss
  • Students without chronic illness
  • Students without severe psychological disorders

Exclusion criteria

Exclusion Criteria:

  • Students with diagnosed hearing loss
  • Students with any chronic illness
  • Students with severe psychological disorders
  • Students outside the defined age range
  • Students who are illiterate
  • Students with intellectual disabilities
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
600 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of misophonia in high school students

    The proportion of high school students identified as having misophonia based on predefined classification criteria using the Amsterdam Misophonia Scale-Revised (AMISOS-R). The AMISOS-R total score ranges from 0 to 40, with higher scores indicating greater misophonia severity. Misophonia classification is determined according to established cutoff values.

    Time frame: Baseline (single assessment)

Secondary outcomes

  1. Severity levels of misophonia symptoms

    Distribution of students according to misophonia severity levels (normal, mild, moderate, and severe) based on the Amsterdam Misophonia Scale-Revised (AMISOS-R). The AMISOS-R total score ranges from 0 to 40, with higher scores indicating more severe misophonia symptoms.

    Time frame: Baseline (single assessment)

07

Study locations

2 of 2 sites recruiting
  • Selected High Schools in Kayseri
    Kayseri, Turkey (Türkiye)
    Recruiting
  • Selected High Schools in Samsun
    Samsun, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07469033
Lead sponsor
Ondokuz Mayıs University
Responsible party
Handan Turan Dizdar (Assistant Professor, Ondokuz Mayıs University) — Principal investigator
First posted
Mar 13, 2026
Start date
Jan 25, 2025
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Mar 13, 2026

Study contacts

Handan Turan Dizdar, PhD
Contact
handan.dizdar@omu.edu.tr
+905055970627
Asya Sıla Alacahan
study director · Ondokuz Mayıs University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion